ARCH Venture Management, LLC
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 15, 2024), ARCH Venture Management, LLC reported 8 stock positions worth $80.3 million. Its top holding was Verve Therapeutics (VERV) at 33.2% of the portfolio, followed by Erasca (ERAS, 28.4%) and Gossamer Bio (GOSS, 11.8%). Compared with Q4 2023, it opened 2 new positions and sold out of 1. The biggest buy was a new position in Q32 Bio (QTTB) and the biggest sale an exit from Revolution Medicines (RVMD).
- Most Recent 13F
- Q2 2026
- Location
- CHICAGO, IL
- CIK
- 0001274403
- Portfolio Value
- $80.3M (Q1 2024)
- SEC Filing
- 0001012975-24-000230 ↗ filed May 15, 2024
Holdings Value
Holdings 8 stocks · $80.3M
| VERV Verve Therapeutics Inc. | 33.23% | 2,008,809 | $26.7M | No change |
| ERAS Erasca Inc. | 28.37% | 11,055,554 | $22.8M | No change |
| GOSS Gossamer Bio Inc. | 11.84% | 8,055,916 | $9.5M | No change |
| DNLI Denali Therapeutics Inc. | 9.75% | 381,249 | $7.8M | No change |
| QTTB Q32 Bio Inc. | 6.80% | 320,482 | $5.5M | New |
| CERO THERAPEUTICS HLDGS INC | 5.52% | 1,444,296 | $4.4M | New |
| SINGULAR GENOMICS SYSTEMS IN | 2.43% | 3,798,926 | $2.0M | No change |
| UNBX Unity Biotechnology Inc. | 2.05% | 1,004,817 | $1.6M | No change |
Portfolio Sells Q4 2023 → Q1 2024
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −56.72 |
Portfolio Buys Q4 2023 → Q1 2024
| QTTB Q32 Bio Inc. | New | 6.80% | +6.80 |
| CERO THERAPEUTICS HLDGS INC | New | 5.52% | +5.52 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 12 | $1.1B | PBLS, BEAM, RAPP, SPTX, ERAS |
| Q1 2026 | 10 | $677.1M | MAZE, RAPP, VIR, ERAS, BEAM |
| Q4 2025 | 9 | $651.7M | MAZE, BEAM, RAPP, LYEL, VIR |
| Q3 2025 | 9 | $492.4M | RAPP, BEAM, MAZE, VIR, LYEL |
| Q2 2025 | 11 | $299.1M | BEAM, VIR, MAZE, RAPP, VERV |
| Q1 2025 | 9 | $206.2M | BEAM, MAZE, RAPP, ERAS, VERV |
| Q4 2024 | 9 | $230.2M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q3 2024 | 9 | $260.6M | BEAM, RAPP, ERAS, QTTB, VERV |
| Q2 2024 | 9 | $266.0M | BEAM, RAPP, ERAS, VERV, GOSS |
| Q1 2024 | 8 | $80.3M | VERV, ERAS, GOSS, DNLI, QTTB |